Oligonucleotide compositions and methods thereof

Inventors

Zhang, Jason Jingxin • SHIVALILA, CHIKDU SHAKTI • Vargeese, Chandra • Iwamoto, Naoki

Assignees

Wave Life Sciences Pte Ltd

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11596646-B2

Patent

Publication Date

2023-03-07

Expiration Date


Abstract

Among other things, the present disclosure provides technologies for altering splicing, particularly for increasing inclusion of exons in splicing products. In some embodiments, the present disclosure provides SMN2 oligonucleotides, compositions, and methods thereof. In some embodiments, the present disclosure provides chirally controlled SMN2 oligonucleotide compositions. In some embodiments, provided oligonucleotides and compositions can increase level of an exon 7-containing SMN2 splicing product and/or a gene product thereof. In some embodiments, the present disclosure provides methods for treatment of splicing-related conditions, disorders and diseases. In some embodiments, the present disclosure provides methods for treating SMN2-related conditions, disorders and diseases such as SMA (spinal muscular atrophy) and ALS (amyotrophic lateral sclerosis).

Core Innovation

The invention relates to a composition comprising a plurality of oligonucleotides of a particular oligonucleotide type defined by a base sequence, a pattern of backbone linkages, a pattern of backbone chiral centers, and a pattern of backbone phosphorus modifications. The base sequence comprises 15 contiguous bases of TCACTTTCATAATGCTGG (SEQ ID NO: 479), wherein each T can be independently substituted with U. The oligonucleotides are further defined by backbone chirality and phosphorus-modification patterns rather than by sequence alone.

The oligonucleotides comprise at least 5 chiral modified internucleotidic linkages, each independently having a stereopurity of at least 90% at its chiral linkage phosphorus. The pattern of backbone chiral centers is or comprises formula forms using Rp, Sp, and Op in combination with Np/Op elements, where each Np is independently Rp or Sp and Op indicates an achiral linkage phosphorus of a natural phosphate linkage. The claimed backbone pattern constrains which internucleotidic linkages present chirality at linkage phosphorus.

The disclosure further includes conjugation and targeting embodiments involving additional chemical moieties such as ASGPR-binding moieties, including GalNAc-related structures, and linker architectures for attachment to oligonucleotide chains. It also describes SMN2-targeting oligonucleotides and their association with increasing inclusion of SMN2 exon 7 in transcript splicing systems, together with broader oligonucleotide modality contexts and pharmaceutical formulation concepts.

Claims Coverage

The independent claim defines a composition of oligonucleotides by a specific 15-base sequence together with patterned control over backbone linkages, chiral centers, and backbone phosphorus modifications. Across the provided claims, the core inventive features center on chirally controlled backbone stereochemistry, quantified stereopurity at chiral linkage phosphorus, and optional receptor-binding or sequence-specific refinements.

15-base sequence with T-to-U substitution

The composition comprises a plurality of oligonucleotides defined by a base sequence comprising 15 contiguous bases of TCACTTTCATAATGCTGG (SEQ ID NO: 479), where each T can be independently substituted with U.

Patterned backbone linkage, chiral center, and phosphorus modifications

The oligonucleotides are defined by a pattern of backbone linkages, a pattern of backbone chiral centers, and a pattern of backbone phosphorus modifications.

At least 5 chiral modified internucleotidic linkages with stereopurity

The oligonucleotides comprise at least 5 chiral modified internucleotidic linkages, each independently having a stereopurity of at least 90% at its chiral linkage phosphorus.

Backbone chiral-center pattern defined by Rp/Op and Np/Sp formulas

The pattern of backbone chiral centers is or comprises one of the provided formula forms using Rp, Sp, Np, and Op, wherein each Np is independently Rp or Sp and Op indicates an achiral linkage phosphorus of a natural phosphate linkage.

Additional ASGPR-binding chemical moiety

Each oligonucleotide includes an additional chemical moiety that can bind to the asialoglycoprotein receptor.

Overall, the claim coverage centers on a composition defined by a specific 15-base sequence with optional T-to-U substitution, combined with structured backbone linkage, chiral-center, and phosphorus-modification patterns. The claims require at least five stereopure chiral modified internucleotidic linkages and further include optional ASGPR-binding and SMN2-related refinements.

Stated Advantages

Improves inclusion of SMN2 exon 7 by at least 2-fold versus a reference condition with no composition in an SMN2 transcript splicing system.

Provides receptor targeting via an additional chemical moiety that can bind to the asialoglycoprotein receptor.

GalNAc conjugation is associated with reduced kidney accumulation and increased liver accumulation, improving efficacy.

Improved survival in SMA model mice versus saline for chirally controlled stereopure oligonucleotides and/or GalNAc conjugation.

Supports targeted delivery to liver via asialoglycoprotein receptor (ASGPR) ligands.

The description states reduced immune response/adverse effects versus Nusinersen-like stereorandom SMN2 oligonucleotides.

The description states improved delivery/efficacy versus Nusinersen-like stereorandom SMN2 oligonucleotides.

Improved exon-7 inclusion efficacy at low concentrations.

Longer in vivo efficacy when an additional asialoglycoprotein-receptor binding moiety is included.

Documented Applications

SMN2 transcript splicing system, including increased inclusion of SMN2 exon 7.

Liver delivery via ASGPR targeting using GalNAc-like moieties.

Testing and comparison of SMN2 antisense oligonucleotides in spinal muscular atrophy (SMA) model mice, reporting survival outcomes across stereopure, stereorandom, and GalNAc-conjugated stereorandom versions.

Targeted delivery to liver using asialoglycoprotein receptor (ASGPR) ligand-containing oligonucleotide compositions.

Altering pre-mRNA splicing in an SMN2 transcript splicing system.

Use in SMA patient fibroblasts.

Use in SMA model mice.

Targeting through an additional chemical moiety that can bind to the asialoglycoprotein receptor.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.